The Shot That Makes You Slim. And the Question No One Asks.
Tirzepatide works. Period. But before you decide on the shot, you should have heard the question that doesn't appear in any ad: why aren't you losing weight in the first place? A deep dive through studies, KPNI, anthroposophy, and what really blocks the path.
In my practice, this question comes up almost daily over the past few months. "What do you think of Mounjaro? My colleague injects it. My friend too. She lost 14 kilos in four months. Should I try it as well?" The short answer I give is rarely yes or no. It is: let's first answer two other questions. First, do you know why your body is not currently losing weight? Second, do you know what the shot triggers in your metabolism, the part that isn't in the ad? If after these two answers you still say, I want it, that's your decision. But please not before.
I am not generally against Mounjaro. In severe obesity with established complications, in type 2 diabetes with high cardiovascular risk, in people who have already tried everything, tirzepatide can be a sensible tool. That is the honest truth.
What concerns me: in German consultations, Mounjaro is increasingly being prescribed to people who are five to fifteen kilograms overweight. Who do not eat "wrong." Whose bodies, for deep biological reasons, are not losing weight.
These people often have an untreated thyroid, chronic inflammation, heavy metal exposure, a history of mold, a derailed cortisol rhythm, or estrogen dominance. For them, the shot is not the answer. It is forgetting the question.
This is the article I wished I'd had before the first patients put Mounjaro on my desk. Not as an anti-pharma pamphlet. As a differentiation.
The pharmacology, brief and honest. Then you understand what the shot does, and above all, what it doesn't do.
Mounjaro is the brand name of tirzepatide. Tirzepatide is a peptide injected subcutaneously once a week. It acts as a dual agonist at two hormone receptors at the same time: at the GLP-1 receptor and at the GIP receptor. Both receptors normally respond to hormones your own gut releases after eating. These hormones are called incretins. They lower blood sugar, increase insulin release, and signal satiety to the brain.
Tirzepatide mimics these hormones, but with a half-life of about five days. Your body therefore has a constant satiety signal for an entire week. You eat less because you feel less hunger. Gastric emptying slows. The reward system that normally responds to food with dopamine is dampened. You lose fat. Fast.
RCT, n=2,539Jastreboff et al., 2022, NEJM. The SURMOUNT-1 study
The pivotal phase-3 trial in 2,539 adults with obesity. Tirzepatide once weekly, 72 weeks long. The result was striking: at the highest dose (15 mg), participants lost on average 20.9 percent of their body weight. Over 90 percent lost at least 5 percent. 57 percent lost at least 20 percent.
This is an effect we had never seen before in obesity pharmacology. It comes close to the effect size of gastric bypass surgery, without surgery. That is the other side of the coin. The strong side.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. doi.org/10.1056/NEJMoa2206038
Let that sink in. If the shot has such massive effects, where is the catch? The answer is not in the commercials. It is in the accompanying studies, in the phase-3 extensions, and in the pharmacology itself.
Muscle loss. Rebound. Reward system. Three aspects that any serious patient education must include.
First: a quarter of the lost weight is muscle mass, not fat
This is the uncomfortable number that almost never appears prominently. With tirzepatide and similar agents, about 25 percent of the weight lost comes from fat-free mass. Fat-free mass is not just water. It is muscle, bone, connective tissue, organ mass, blood components. Exactly what you want to keep as you age.
from fat-free mass
of muscle mass
a decade of aging
Locatelli et al., 2024, Diabetes Care. Incretin therapy and muscle mass
This review in Diabetes Care states it very clearly: GLP-1 and GIP agonists cause a loss of about 10 percent or roughly 6 kilograms of fat-free mass. Comparable to a decade of aging.
The authors stress that muscle mass in old age is central for function, metabolism, and mortality. Anyone who loses 6 kg of muscle in one year between 50 and 60 has a different body afterwards. The recommendation: parallel, supervised resistance training of at least 10 weeks duration and high protein intake. Both are rare in real life.
Locatelli JC, Costa JG, Haynes A, et al. Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? Diabetes Care. 2024;47(10):1718-1730. doi.org/10.2337/dci23-0100
Stefanakis, Kokkorakis, Mantzoros, 2024, Metabolism
This Harvard review explicitly warns of the risk of sarcopenic obesity: a person who weighs less after tirzepatide but, relatively, has even more fat compared to muscle. This can permanently lower metabolic rate, increase fall risk, and accelerate frailty in old age.
The consequence: older people in particular, and those with already low muscle mass, are a high-risk group for exactly the outcome the therapy is supposed to protect them from.
Stefanakis K, Kokkorakis M, Mantzoros CS. The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health. Metabolism. 2024;161:156057. doi.org/10.1016/j.metabol.2024.156057
Second: after stopping, the weight comes back. Quickly.
This is the study that really every person considering the shot should know. It's called SURMOUNT-4. It was published in 2024 in JAMA. The question was simple: what happens when people who lost weight on tirzepatide stop the medication?
RCT, n=670Aronne et al., 2024, JAMA. SURMOUNT-4: what happens after stopping
670 adults with obesity received tirzepatide at maximum tolerated dose for 36 weeks. They lost an average of 20.9 percent of their body weight. Then they were randomly divided into two groups: continued tirzepatide or placebo. 52 more weeks.
The result: the tirzepatide group continued to lose (-5.5 percent additional). The placebo group regained 14.0 percent. Statistically significant. Only 16.6 percent of the placebo group could maintain 80 percent of their original weight loss.
Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction: SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. doi.org/10.1001/jama.2023.24945
Case Series, n=9Kubota et al., 2023, Cureus. What happens 6 months after stopping
A small Japanese case series after SURPASS-J-mono: after stopping tirzepatide, HbA1c and body weight rose dose-dependently. Effects measurable as early as two months. Significant rebound after six months. Strongest at the highest prior dose.
Kubota M, Yamamoto K, Yoshiyama S. Effect on HbA1c and Body Weight After Discontinuation of Tirzepatide. Cureus. 2023;15(10):e46490. doi.org/10.7759/cureus.46490
Tirzepatide is not a cure for obesity. It is a suppression. If you stop, the problem comes back, often with unfavorable body composition, because you've lost muscle mass. The consequence: it is a lifelong therapy, or it is very likely in vain.
Lifelong therapy with a medication whose long-term safety over ten or twenty years no one knows yet, simply because it hasn't been on the market that long. That is an open point that needs to be named honestly.
Third: the reward system is dampened. Including what isn't food.
This is where it gets interesting. GLP-1 and GIP receptors don't just sit in the gut and the islets of the pancreas. They also sit in the hypothalamus, in the mesolimbic dopamine system, in the reward center. That is exactly the trick of why tirzepatide curbs cravings so effectively.
The open question: if I permanently modulate the reward system, am I only dampening the urge for food? Or am I also dampening other rewards? Sex? Music? Enthusiasm? Joy of life?
Reports from practice and first mechanistic studies suggest that some people on GLP-1 agonists describe a kind of emotional flatness, loss of drive, an anhedonia-like mood. That is not listed as a common side effect in the major approval studies, because it is rarely asked about. It is also not yet causally proven. But it is pharmacologically plausible and increasingly documented clinically.
If you are currently depressed, in a phase of life with little joy, in a relationship slump, or in a burnout course, a shot that dampens the reward system can be exactly the wrong time capsule. You do lose weight. But you simultaneously stop feeling what would pull you back into life.
Pancreatitis, gastroparesis, thyroid C-cell warning. And what we simply don't know about long-term effects.
Real-World Cohort, n=10,328Aldhaleei et al., 2024. GI side effects under GLP-1 agonists
This All-of-Us cohort analysis with over 10,000 adults in the US captured the real-world side-effect frequencies of GLP-1 agonists in everyday use. The numbers are clearly above what is mentioned in many consultations.
Abdominal pain 57.6 percent. Constipation 30.4 percent. Diarrhea 32.7 percent. Nausea and vomiting 23.4 percent. Gastroparesis 5.1 percent. Pancreatitis 3.4 percent. Gastrointestinal bleeding 15.9 percent. These numbers are not trivial. They are very unevenly distributed in everyday practice.
Aldhaleei WA, Abegaz TM, Bhagavathula AS. Glucagon-like Peptide-1 Receptor Agonists Associated Gastrointestinal Adverse Events. Pharmaceuticals. 2024;17(2):199. doi.org/10.3390/ph17020199
Tirzepatide carries a black box warning from the FDA in the US for medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2. This warning comes from animal data in rats, in which GLP-1 agonists triggered C-cell tumors of the thyroid. In humans this has not yet been clearly demonstrated, but the signal is strong enough to contraindicate the substance in pre-existing or familial risk.
Practically: anyone with a family history of thyroid cancer should not receive tirzepatide without discussing it in detail.
Reiss et al., 2025, Biomolecules. GLP-1 therapy and paths to discontinuation
This recent review summarizes the risks soberly: GI side effects common, pancreatitis and bowel obstruction rarer but real. Loss of muscle mass, premature facial skin aging ("Ozempic face"), and above all the high rate of weight regain after stopping. The authors advocate a strategy in which patients are first stabilized, then gently weaned, with simultaneous lifestyle implementation. In reality, this support structure is missing almost everywhere.
Reiss AB, Gulkarov S, Lau R, et al. Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss. Biomolecules. 2025;15(3):408. doi.org/10.3390/biom15030408
You're not losing weight. But is it really about the food or the exercise? Or is it about something else?
Here is the question almost never asked before the shot lands on the table. The answer decides whether the shot makes any sense at all, or whether it is just an expensive suppression of an unsolved biological blockage.
You are not too weak. You are not too undisciplined. You are not the reason your body is holding on to fat. Your body is holding on to fat because right now it has good reasons to hold on. These reasons are called hormones, inflammation, toxins, stress, sleep. If we don't look at them, every diet and every shot is a cosmetic solution against a biological wall.
In my practice I repeatedly see people who have not lost weight for years, even though they seem to be doing everything right. When we diagnose properly, we almost always find one or several of the following factors. They are part of standard practice in almost no obesity consultation. They should be.
Khalil et al., 2023. Environmental toxins as adipogens
This review summarizes how persistent organic pollutants (POPs) and heavy metals disrupt metabolic function: POPs influence adipogenesis directly, heavy metals disturb glucose regulation via pancreatic beta cells and insulin signaling pathways. Endocrine disruptors in the prenatal phase raise fasting glucose later in life.
What this means: part of your present metabolic reality is not the result of what you ate yesterday. It is the result of what your mother breathed, what was in the water of your childhood, what was in the dental fillings of your grandparents.
Khalil WJ, Akeblersane M, Khan AS, Moin ASM, Butler AE. Environmental Pollution and the Risk of Developing Metabolic Disorders. Int J Mol Sci. 2023;24(10):8870. doi.org/10.3390/ijms24108870
Sanyal & Raychaudhuri, 2016. Hypothyroidism and obesity
This Indian review makes it clear: between hypothyroidism and obesity there is a bidirectional relationship. Hypothyroidism lowers basal metabolic rate and leads to moderate weight gain. Conversely, obesity itself produces a secondary hyperthyrotropinemia via elevated leptin levels. Both reinforce each other.
The consequence: in obesity with elevated TSH, primary Hashimoto's must be distinguished from secondary obesity-related TSH elevation. Thyroid antibodies help with this.
Sanyal D, Raychaudhuri M. Hypothyroidism and obesity: An intriguing link. Indian J Endocrinol Metab. 2016;20(4):554-557. doi.org/10.4103/2230-8210.183454
Adam & Epel, 2007. Stress, eating, reward
This widely cited review on the stress-eating hypothesis shows: chronic stress activates the HPA axis, raises cortisol, promotes visceral belly fat, and shifts the reward system toward calorie-rich, highly palatable food. The authors describe "reward-based stress eating" as a model in which cortisol, insulin, leptin, and NPY interact to raise the reward value of food.
The consequence: under chronic stress, your brain is working against you. Tirzepatide can mask this. Tirzepatide cannot solve the stress.
Adam TC, Epel ES. Stress, eating and the reward system. Physiol Behav. 2007;91(4):449-458. doi.org/10.1016/j.physbeh.2007.04.011
Obesity is not an energy problem. It is a communication problem between the nervous system, the immune system, the hormone system, and metabolism.
In clinical psycho-neuro-immunology we don't only look at calories. We look at the interplay of four systems. Obesity arises when these four systems no longer talk to each other but only fight for their own stability.
Nervous System
The vagus nerve regulates satiety, appetite, digestion, and inflammation via the gut-brain axis. Under chronic stress, low vagal activity, and disturbed HRV, you lose the normal sensation of fullness. Tirzepatide replaces this signal pharmacologically. It does not repair the vagus.
Immune System
Fat tissue is an immunological organ. In obesity it is chronically inflamed. This inflammation blocks leptin and insulin signaling pathways in the hypothalamus. You eat, but your brain doesn't register it. As long as the inflammation runs, sustained weight loss is physiologically harder.
Metabolism
Insulin resistance is not the end stage. It is the beginning. It blocks fat burning and forces your body to store fat instead of mobilizing it. Anyone wanting to lose weight must first restore insulin sensitivity. Only then does the fat flow.
Hormone System
Thyroid, sex hormones, cortisol, leptin, ghrelin, GLP-1, GIP, insulin, adiponectin. They all direct whether your body runs in build-up or break-down mode. If just one of these hormones is out of balance, it can block all the others. Tirzepatide intervenes there at one point. The system is more than one point.
These four lenses explain why a shot that intervenes at only one point is often not enough. And why it sometimes pushes the system further out of balance.
How would Rudolf Steiner classify tirzepatide? A question never asked in conventional medicine, and therefore all the more important.
Anthroposophic medicine has a different language than conventional medicine. It complements conventional medicine, it does not replace it. If you want to read more about the scientific foundations of anthroposophic medicine, you can find that in my article Whoever Heals, Is Right.
Steiner describes the human being as a being with four members. This is not esoteric muddle. It is a very precise functional description that achieves more in one respect than purely material conventional medicine: it can describe what happens in metabolism when consciousness, joy of life, the inner warmth of a person, are deprived of something by a therapy.
If metabolism is the work of the I, what happens when we move it to the outside?
In Steiner's description, the metabolism of the human being is not a passive chemical process. It is an activity. One in which the I of the human being penetrates the world it has taken in, transforms it, makes it its own. The human eats the world and from it makes themselves. This transformation does not happen in the refrigerator of the body. It happens as an active, warm, individual act.
If I now give a medication that produces satiety signals from the outside, that dampens the reward system, that slows the stomach, then the medication takes over tasks that, in Steiner's model, belong to the activity of the I. The I no longer experiences itself as regulator. It experiences itself as regulated. Long enough taken, this could, the anthroposophic tradition suspects, lead to the I losing its own activity in relation to metabolism. To the inner warmth that goes along with enjoyment, with desire, with active living, being dampened.
This fits with what patients on GLP-1 agonists sometimes describe: a feeling of "life on low burn." A loss of enjoyment, not just of hunger. A loss of warmth, in both the literal and figurative sense.
This view is not a scientific study. It is a complement. It helps perceive symptoms that aren't queried in the double-blind trial. It makes us alert to a question beyond weight: is this person actually still living their life, or a dampened version of it?
The truth probably lies in between. Tirzepatide is not "evil." But it is also not harmless. It is a technological intervention into a central self-regulation. Anyone who has understood that will dose, accompany, and use the shot differently than someone who treats it as a slimming drug.
My diagnostic path, before we even talk about tirzepatide.
When someone comes to me with the wish for Mounjaro, it is not about a prescription with me. It is about understanding. Before I even come close to a prescription, I ask these questions and run this diagnostic.
What should be checked before a tirzepatide decision
- Thyroid full panel: TSH, fT3, fT4, TPO-Ab, TG-Ab, reverse T3
- Insulin and glucose: fasting glucose, fasting insulin, HOMA-IR, HbA1c
- Lipids full panel: triglycerides, HDL, LDL including subclasses, Apo-B, Lp(a)
- Inflammation markers: hs-CRP, IL-6, ferritin, homocysteine
- Hormones: salivary cortisol daily profile, sex hormones cycle-dependent (in women day 19 to 22), free and total testosterone (in men), DHEA-S, SHBG
- Micronutrients: vitamin D, B12, folate, magnesium, zinc, selenium, iron status
- Toxins where clinically suspected: heavy metals (whole blood, where appropriate provoked), mycotoxins in urine
- Lifestyle history: sleep architecture, stress load, exercise, sun, social bonds
- Biographical history: when did the weight plateau begin, what happened at the same time, is there a traumatic event as trigger
That sounds elaborate. It is elaborate. But it is the only way to see a human being instead of seeing a BMI number. And it is the prerequisite for tirzepatide, if it is given at all, to be embedded in a healing path and not in a vacuum.
Three levers that almost always work, before we even talk about shots
First, restore insulin sensitivity. Fast carbohydrates out, especially after 6 PM. Three meals per day, no snacks. Movement built into the day, ideally before or directly after meals. Sleep from 10 PM to 6 AM in the dark season. These four levers alone measurably increase insulin sensitivity in four to eight weeks.
Second, strength training three times per week, at least 30 minutes. Muscle is the only tissue that takes up glucose independently of insulin. More muscle means higher metabolic rate, better glucose regulation, lower fall risk, and in the long run a longer life expectancy. That doesn't replace a shot, that replaces an entire metabolic mode.
Third, switch off the real blockages. If diagnostics show one of them: properly treat Hashimoto's. Detox heavy metals. Remediate mold exposure. Restore estrogen balance. Correct cortisol rhythm. Each of these interventions can resolve a plateau that previously seemed immovable.
If after all this it becomes clear in six to twelve months that pharmacological support makes sense, tirzepatide can be a tool. Not the first. Sometimes not the right one. Sometimes very much the appropriate one. But then with eyes that are open, with strength training as mandatory companion, with high-quality protein intake, with a clear weaning strategy, and with knowledge of what you are doing.
You don't have to choose between "shot or stay as you are." That choice was sold to you wrong.
The advertising narrative goes: you suffer from your weight, other methods don't work, here is the modern solution. This narrative blanks out that most people who don't lose weight have never been truly diagnosed. Their thyroid was never fully checked, never their cortisol profile, never their heavy metal load, never their insulin resistance, never their stress, their sleep, their hormones.
You can reject both. The fatalistic version "well, then I'll just live with overweight." And the quick fix "then I'll take the shot and everything will be fine." You can choose instead the path that is more work and more truth. The path that asks: why is my body holding on to fat? What is it telling me with this? And what underneath is the real healing?
Energy, clarity, joy of life, warmth. These are the real goals. Not a BMI number on a slip of paper. Not a quick change in the mirror that disappears with rebound after stopping.
Three things you can do this week before even thinking about the shot.
First, get a full diagnostic done. TSH alone is not enough. Get the entire thyroid done. Cortisol daily profile. HOMA-IR. Hormones. If your family doctor doesn't do this, you can ask a holistically oriented physician. Not every health insurance pays for it. But it can bring much more clarity than twenty years of unsuccessful dieting.
Second, focus first on insulin resistance and sleep. Fast carbohydrates out, three meals per day, no snacking, sleep from 10 PM to 6 AM. Strength training three times per week. These four levers alone measurably change your metabolic profile in two to three months. Before any shot. Before any diet.
Third, ask yourself honestly why your body is holding on to fat. What was happening in your life when the plateau began? Stress, grief, sleeplessness, a pregnancy, a burnout, mold in your apartment, a flare-up of a chronic condition? This biographical question is medically often more important than any laboratory number.
If you don't just want to read but really understand why your body is currently not losing weight, and whether tirzepatide makes any sense at all for you or not, you can book an appointment below this article. Together we then go through all the axes. With the differentiated view this topic deserves.
Sources
Tirzepatide: efficacy and study landscape
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. doi.org/10.1056/NEJMoa2206038 [SURMOUNT-1, RCT, n=2,539]
Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. doi.org/10.1001/jama.2023.24945 [SURMOUNT-4, RCT, n=670, discontinuation study]
Kubota M, Yamamoto K, Yoshiyama S. Effect on HbA1c and Body Weight After Discontinuation of Tirzepatide. Cureus. 2023;15(10):e46490. doi.org/10.7759/cureus.46490 [Case series, rebound after stopping]
Tirzepatide: risks and side effects
Locatelli JC, Costa JG, Haynes A, et al. Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? Diabetes Care. 2024;47(10):1718-1730. doi.org/10.2337/dci23-0100 [Review, muscle mass loss]
Stefanakis K, Kokkorakis M, Mantzoros CS. The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health. Metabolism. 2024;161:156057. doi.org/10.1016/j.metabol.2024.156057 [Review, sarcopenia risk]
Aldhaleei WA, Abegaz TM, Bhagavathula AS. Glucagon-like Peptide-1 Receptor Agonists Associated Gastrointestinal Adverse Events. Pharmaceuticals (Basel). 2024;17(2):199. doi.org/10.3390/ph17020199 [Real-world cohort, n=10,328]
Reiss AB, Gulkarov S, Lau R, et al. Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss. Biomolecules. 2025;15(3):408. doi.org/10.3390/biom15030408 [Review, discontinuation strategies]
What prevents weight loss: hormonal, immunological, toxicological
Sanyal D, Raychaudhuri M. Hypothyroidism and obesity: An intriguing link. Indian J Endocrinol Metab. 2016;20(4):554-557. doi.org/10.4103/2230-8210.183454 [Review]
Artasensi A, Mazzolari A, Pedretti A, Vistoli G, Fumagalli L. Obesity and Type 2 Diabetes: Adiposopathy as a Triggering Factor. Molecules. 2023;28(7):3094. doi.org/10.3390/molecules28073094 [Review, obesity and inflammation]
Khalil WJ, Akeblersane M, Khan AS, Moin ASM, Butler AE. Environmental Pollution and the Risk of Developing Metabolic Disorders: Obesity and Diabetes. Int J Mol Sci. 2023;24(10):8870. doi.org/10.3390/ijms24108870 [Review, obesogens and heavy metals]
Adam TC, Epel ES. Stress, eating and the reward system. Physiol Behav. 2007;91(4):449-458. doi.org/10.1016/j.physbeh.2007.04.011 [Mechanism review, cortisol and visceral fat]